ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune …

ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune …
SEATTLE–(BUSINESS WIRE)–ALLOZYNE ANNOUNCES POSITIVE PROOF OF CONCEPT DATA FOR AZ17, A BISPECIFIC TH17 ANTAGONIST FOR TREATMENT OF AUTOIMMUNE DISEASES
Read more on Business Wire

EFSA updates GM risk assessment guidance
The European Food Safety Authority (EFSA) has updated its guidance for assessing the environmental risk that genetically modified plants may pose to take account of new scientific expertise.
Read more on Food Navigator Europe

ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune …
ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.
Read more on Business Wire via Yahoo! Finance